Executives at Amgen (NASDAQ:AMGN) outlined several upcoming clinical milestones and recent data updates across its ...

Amgen is running a number of studies of its obesity drug, MariTide.

Amgen has denied a request by the FDA to voluntarily withdraw its rare disease drug Tavneos from the market, the company said ...

Amgen Inc. ( NASDAQ:AMGN ) has announced that it will be increasing its dividend from last year's comparable payment ...

But Amgen’s true success stems from putting people first. By creating an environment where innovation, inclusion and ...

The decision by the EC was supported by data from the Myasthenia Gravis Inebilizumab Trial.

By Deena Beasley Feb 3 (Reuters) - Amgen on Tuesday reported fourth-quarter financial results that came in ahead of Wall ...

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...

Piper Sandler Virtual Novel Targets in Immunology Symposium February 12, 2026 5:00 PM ESTCompany ParticipantsPaul Burton - Senior VP ...

The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of ...

A Phase III readout in September 2024 for rocatinlimab, on which Amgen and Kyowa Kirin were collaborating in atopic dermatitis, appeared underwhelming to analysts, with Jefferies noting that the data ...

When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of distribution while simultaneously ...